STRO earnings: real EPS beat/miss history, analyst consensus Buy, P/E -0.08. Updated 2026-07-23.
Sutro Biopharma (STRO) Research Hub
Sutro Biopharma (STRO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 16.86 USD (-8.17%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.08, market cap 0.23B. This hub links to the full technical, earnings and options research available for STRO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 16.86 USD (-8.17%) |
| 52-week range | 16.48 USD – 33.63 USD |
| Trend regime | Range |
| 14-day RSI | 14.5 (Oversold) |
| Trailing P/E | -0.08 |
| Market cap | 0.23B |
| Dividend yield | 0.00% |
Available research for STRO
Covered Call on STRO: how it works, illustrative setup around the real 16.86 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on STRO: how it works, illustrative setup around the real 16.86 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on STRO: how it works, illustrative setup around the real 16.86 USD price, max profit/loss, breakeven and when to use it. Educational.
STRO technical analysis: range, last 16.86 USD, RSI 14.5, 52w range 16.48 USD–33.63 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is STRO in?
Sutro Biopharma (STRO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is STRO in an uptrend or downtrend?
As of 2026-09-11, STRO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is STRO's trailing P/E ratio?
STRO's trailing P/E is -0.08, with a market cap of 0.23B. See the earnings research page for full valuation detail.